Coultreon Biopharma is a clinical-stage biopharmaceutical company developing first-in-class, orally available small-molecule therapies for chronic inflammatory and autoimmune diseases. Its lead candidate, COL-5671, is a highly selective SIK3 inhibitor designed to simultaneously modulate multiple inflammatory pathways while preserving immune regulatory function. The company leverages an AI-augmented drug design platform trained on over 300,000 compounds to optimize its pipeline.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic inflammatory diseases impose a profound burden on patients, as recurring flares contribute to significant psychological distress and social stigma. Despite advances in targeted therapies, achieving and maintaining disease control remains elusive across multiple chronic indications due to an efficacy ceiling and loss of response, which limit long-term benefit for patients.
Solution
Coultreon Biopharma develops first-in-class, orally available small-molecule therapeutics designed to modulate multiple validated inflammatory pathways simultaneously, addressing the limitations of existing treatments. Its lead candidate, COL-5671, is a highly selective SIK3 inhibitor that mimics the anti-inflammatory effects of intracellular cAMP elevations, simultaneously suppressing pathogenic cytokines such as TNFα, IL-12, and IL-23 while promoting IL-10 production to restore immune balance. This dual action resembles a combination of anti-TNFα and anti-IL-23 therapies in a single molecule, offering the potential to break the therapeutic ceiling of current treatments. The company's AI-augmented drug design platform, trained on a dataset of over 300,000 compounds, integrates AI-driven modeling, structure-based design, and early safety prediction into a continuous learning loop that optimizes lead assets for clinical success.
Target Audience
Primary customers are patients with chronic immune-mediated inflammatory diseases such as ulcerative colitis and other autoimmune conditions, as well as healthcare providers and clinical partners seeking more effective oral treatment options that overcome the limitations of existing biologic therapies.
Features
- COL-5671 is a first-in-class, highly selective SIK3 inhibitor that has successfully progressed through multiple cohorts in a first-in-human clinical study
- Selective targeting of SIK3 while avoiding SIK2 inhibition, which is associated with dose-limiting safety liabilities
- Once-daily oral dosing with a favorable pharmacokinetic profile, including a long half-life and low inter-participant variability
- Demonstrated potent and sustained pharmacodynamic activity with strong inhibition of key inflammatory cytokines in human blood
- Proprietary AI-augmented drug design platform trained on over 300,000 compounds, integrating AI-driven modeling, structure-based design, early safety prediction, and human dose projections
- Design-Predict-Make-Test-Analyze cycle that continuously learns from experimental results and provides real-time feedback to scientists